AtCor Medical, the developer and marketer of the SphygmoCor system, which measures central blood pressures and arterial stiffness noninvasively, today announced that it has signed a new agreement to supply SphygmoCor systems and clinical trial support services to a major international pharmaceutical company. The $1.77 million contract is with an existing AtCor customer.
Duncan Ross, AtCor Medical CEO, said, “AtCor has closed new contracts valued at $2.9 million since March, demonstrating the resurgence of the pharmaceutical clinical trial sector since the US healthcare reform legislation was signed. This significant contract confirms AtCor’s market position as the leading provider of noninvasive central blood pressure and arterial stiffness measurement in clinical trials. It also shows that AtCor’s reputation for high levels of customer satisfaction is being rewarded through expanded business with long-term clients.”
Mr. Ross added, “Scientific publications continue to reinforce the importance of using central blood pressure as a measurement. This mounting body of evidence helps to drive our sales in the pharmaceutical clinical trials market and supports the accelerated adoption of SphygmoCor in clinical practice. Understanding a drug’s effect on central pressure is vitally important in assessing efficacy and assuring drug safety in clinical trials. It is equally important in patient care.”
